Table 4.
OR with 95% CI of developing MS among subjects categorized by EBNA1 status and smoking, stratified by DRB1*15:01 status.
| EBNA-1 IgG | Smoking | DRB1*15:01 positive subjects | DRB1*15:01 negative subjects | ||||
|---|---|---|---|---|---|---|---|
| ca/coa | OR (95% CI)b | OR (95% CI)c | ca/coa | OR (95% CI)b | OR (95% CI)c | ||
| Low | Never | 329/401 | 1.0 (reference) | 1.0 (reference) | 360/1255 | 1.0 (reference) | 1.0 (reference) |
| Low | Current | 223/192 | 1.4 (1.1–1.8) | 1.5 (1.2–1.9) | 282/622 | 1.6 (1.3–1.9) | 1.6 (1.3–2.0) |
| High | Never | 1306/526 | 3.0 (2.5–3.6) | 2.9 (2.4–3.5) | 779/1116 | 2.5 (2.1–2.8) | 2.5 (2.2–3.0) |
| High | Current | 1100/272 | 4.9 (4.1–6.0) | 4.9 (4.0–6.0) | 720/615 | 4.0 (3.5–4.8) | 4.1 (3.5–4.9) |
| AP 0.3 (0.1–0.4) | AP 0.3 (0.1–0.4) | ||||||
AP with 95% CI between high EBNA1 IgG and smoking.
aNumber of exposed cases and controls
bAdjusted for age, sex, residential area, study, and ancestry; cAdjusted for age, sex, residential area, study, ancestry, adolescent body mass index, past IM, DRB1*0301, DRB1*1303, DRB1*0801, A*0201, B*4402, B*3801, B*5501, DQA1*0101, DQB1*0302, DQB1*0301, homozygote correction for DRB1*1501, DRB1*0301, and A*0201.